PACS Group, Inc. — Medical Care Facilities. Scored on the same transparent 7-signal model behind the daily rankings.
★
PACS
PACS Group, Inc. · Medical Care Facilities
FCF$151mC
Rev+22.2%A-
D/E3.36D
P/E28.2xB
PEG1.30B
70.5Score
$43.22$6.8B
1Y Target$50.83Analyst consensus · 6 analysts
5Y Target$74.43Compound horizon
10Y Target$110.40Long-dated conviction
FCF$151mTTM · 03/26C
FCF $151m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+22.2%TTM YoYA-
Revenue +22.2% — strong growth, well above S&P median (~7%)
D/E3.36D
D/E 3.36 — most levered decile in Healthcare (≈95th pctile)
P/E28.2xB
P/E 28.2 — near the Healthcare median (≈60th pctile)
PEG1.30B
PEG 1.30 — acceptable premium for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 70.5
Quality0.60
Growth1.00
Value0.58
Why this score
Diluting shareholders
Short track record
Entry · Margin of safety
52-week rangeNear 52-week high
6% off the 12-month high
vs DCF fair value182% aboveest. fair value ~$15
What the price assumes: free cash flow compounding at ~32% a year for the next decade — vs the ~7% a year our model projects from current growth and analyst estimates.
Quality signals · context only
ROIC23.4% · Areturn on invested capital — not score-weighted
Why now
Medical Care Facilities · market cap $6.8b. 6% off the 52-week high of $45.89. Revenue growing +22%, comfortably above the S&P median. 6 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $50.83 (implying +18% upside).
Moat
ROE 24% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
D/E 3.36 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Net margin 4.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $50.83 (6-analyst consensus) — fundamentals + valuation re-rating. 5 yr $74.43 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $110.40 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · PACS
Trend
-1.5 over 15 daily scores
From 72.0 (Jun 22) → 70.5 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · PACS
$
%
%
Shares to buy
46
Position size
$1,988
4.0% of portfolio
Stop price
$32.41
25% below $43.22
$ at risk if stopped
$497.03
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
PACS Group, Inc. (PACS): score, valuation & FAQ
PACS Group, Inc. (PACS) is a Medical Care Facilities company that scores 70.5 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A-), while D/E (D) rate weaker. On valuation, PACS sits about 182% above our discounted-cash-flow fair value — the current price implies roughly 32% annual free-cash-flow growth over the next decade.
Is PACS a good stock to buy?
Bull Rankings scores PACS 70.5 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A-). A score is a quantitative screen of PACS Group, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does PACS score 70.5 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). PACS earns its highest marks on Rev (A-), and is held back by D/E (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is PACS overvalued or undervalued?
Based on $43.22, PACS sits about 182% above our discounted-cash-flow fair value — the current price implies roughly 32% annual free-cash-flow growth over the next decade. It trades at a 28.2x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in PACS?
D/E 3.36 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Net margin 4.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.